Erytech Pharma

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation. While placing the patient at the heart of our priorities, demonstrating ethics and respect towards each person, Erytech is focused on becoming a global leader in rare cancer and orphan diseases space. Since our inception, our mission has been to make a sustained investment in R&D in order to meet the challenges of public health and to offer innovative therapies to target markets with high unmet medical needs, particularly in the field of cancer. Our company has been classified as a Pharmaceutical Facility while developing our activities in close collaboration with health professionals, particularly physicians and pharmacists.
Company Growth (employees)
Lyon, FR
Size (employees)
85 (est)+12%
Erytech Pharma was founded in 2004 and is headquartered in Lyon, FR

Erytech Pharma Office Locations

Erytech Pharma has offices in Lyon and Cambridge
Lyon, FR (HQ)
60 avenue Rockefeller

Erytech Pharma Data and Metrics

Erytech Pharma Financial Metrics


Market capitalization (25-Sep-2017)

234.2 m

Closing share price (25-Sep-2017)

Erytech Pharma's current market capitalization is €234.2 m.
Show all financial metrics

Erytech Pharma Market Value History

Traffic Overview of Erytech Pharma

Erytech Pharma Online and Social Media Presence

Erytech Pharma Company Life and Culture

You may also be interested in